There are currently 603 clinical trials in Omaha, Nebraska looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Nebraska Medical Center, Creighton University Medical Center, Nebraska Methodist Hospital and Alegent Health Bergan Mercy Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807
Recruiting
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observa... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha, Nebraska +4 locations
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
OCS™ Lung TOP Registry For Donor Lungs for Transplantation
NCT03639025
Recruiting
Single-arm, prospective, multi-center, post-approval U.S. registry
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Nebraska Medical Center, Omaha, Nebraska
Conditions: Lung Transplantation
Register for Updates
Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
NCT04925024
Recruiting
The purpose of this study is to test whether Lomecel-B™ works in treating patients with hypoplastic left heart syndrome (HLHS) and to gather additional information about the safety of Lomecel-B. Lomecel-B contains human mesenchymal stem cells (MSCs) as the active ingredient. MSCs are special cells in the body that are able to change into other types of cells, such as heart, blood, and muscle cells. MSCs are found in various tissues of the body, such as the bone marrow, which is the spongy tissue... Read More
Gender:
All
Ages:
12 months and below
Trial Updated:
04/07/2024
Locations: Children's Nebraska, Omaha, Nebraska
Conditions: Hypoplastic Left Heart Syndrome
Register for Updates
Neuropsychological and Behavioral Testing in Younger Patients With Cancer
NCT00772200
Recruiting
This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.
Gender:
All
Ages:
1 month and above
Trial Updated:
04/05/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Childhood Malignant Neoplasm
Register for Updates
Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
NCT04683848
Recruiting
The purpose of this study is to compare the efficacy and safety of intravenous (IV) infusions of MT-3921 to placebo in subjects with acute traumatic cervical spinal cord injury. Subjects meeting eligibility criteria will enter the 6-month double-blind period. Subjects will be randomized in a 2:1 ratio to receive MT-3921 or placebo in a double blind manner.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/05/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Spinal Cord Injury
Register for Updates
Harmony TPV Post-Approval Study
NCT05077774
Recruiting
The purpose of this study is to characterize the functionality of transcatheter implantation of the Medtronic Harmony Transcatheter Pulmonary Valve (TPV) achieved by real-world implanters.
Gender:
All
Ages:
All
Trial Updated:
04/04/2024
Locations: Children's Hospital & Medical Center, Omaha, Nebraska
Conditions: Congenital Heart Disease, Tetrology of Fallot, RVOT Anomaly, Pulmonary Regurgitation
Register for Updates
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
NCT05605522
Recruiting
This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: XCancer Omaha / Urology Cancer Center, Omaha, Nebraska
Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer, Ewing Sarcoma, NTSR1 Expressing Solid Tumours, Neuroendocrine Differentiated (NED) Prostate Cancer
Register for Updates
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
NCT05878184
Recruiting
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Register for Updates
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Alegent Health Immanuel Medical Center, Omaha, Nebraska +4 locations
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT05806515
Recruiting
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with h... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Alegent Health Immanuel Medical Center, Omaha, Nebraska +3 locations
Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Register for Updates
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
NCT05287399
Recruiting
This is a Phase 1, open-label, multicenter, single-arm, dose escalation study, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of single-agent ASC61(an orally bioavailable small-molecule inhibitor of PD-L1) in subjects with advanced solid tumors for whom no standard therapy is available.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Nebraska Cancer Specialists, Omaha, Nebraska
Conditions: Advanced Solid Tumors
Register for Updates
MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma
NCT05655312
Recruiting
In this first-in human, phase I/IIa study, the safety and efficacy of [212Pb]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated in patients with unresectable and metastatic melanoma.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/02/2024
Locations: Nebraska Cancer Specialists, Omaha, Nebraska
Conditions: Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma, Uveal, Mucosal Melanoma, Melanoma Stage III
Register for Updates